SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Dallas, TX.

United States Antimony Corp.

Investors are actively debating UAMY's role in Western technological sovereignty as the stock benefits from a broader rotation into critical minerals and rare earth plays tied to AI infrastructure and national defense. The community remains hyper-focused on supply chain scarcity and potential institutional accumulation while navigating the persistent volatility and intense short-selling activity typical of this sector.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta shares are facing selling pressure after the company raised its full-year capital expenditure guidance to support ongoing AI infrastructure expansion, sparking concerns about the timeline for return on investment. While the broader market remains resilient, investors are actively debating whether this massive spending surge signals long-term AI leadership or an overextension of the company's balance sheet.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is experiencing significant momentum after the FDA granted priority review to the sNDA for AXS-05 to treat Alzheimer's disease agitation, with a decision expected by April 30, 2026. The community is actively discussing the stock's strong commercial execution, potential for international partnerships, and bullish sentiment following upward analyst price target revisions.

Huachen AI Parking Management Technology Holding Co., Ltd. engages in the provision of smart parking solutions and equipment structural parts. Its products include structural parts, garage structural parts, materials such as customized steel and load bearing steel plates for cubic parking equipment, and railroad accessories. The company was founded by Lu Bin on September 30, 2021 and is headquartered in Jiaxing, China.

Huachen AI Parking Management Technology Holding Co. Ltd. - Ordinary Shares - Class A

Huachen AI Parking Management Technology Holding Ord Shs

HCAI is trending as a low-float, speculative Chinese small-cap stock that community members are actively monitoring for potential short-squeeze activity following a recent reverse stock split. While some traders view the symbol as an opportunity for quick momentum gains, others are warning of a typical pump-and-dump cycle, pointing to limited company transparency and aggressive price volatility.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is seeing increased investor activity and community interest following the start of R2 production and the company's efforts to maintain operational timelines despite recent weather challenges. Discussions are heavily focused on the stock's potential for an earnings-driven breakout, with participants closely debating the company's path to profitability and the impact of the upcoming R2 vehicle launch.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is trending as investors closely watch its earnings performance to gauge the sustainability of the AI infrastructure boom, with the community focused on the company's ability to monetize its massive cloud and AI investments. Market participants are debating how the stock's capital expenditure strategy and growth metrics compare against other mega-cap tech giants amid a volatile period for the sector.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as investors focus on its pivot into AI and cloud infrastructure through the Northern Data acquisition, fueled by significant support from Tether. The community is actively discussing a potential short squeeze, citing high short interest, elevated borrowing costs, and strong insider alignment with the current political administration.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is trending as investors closely monitor its heavy AI capital expenditures, with the community actively debating whether the company's aggressive infrastructure investments in Gemini and Cloud integration will sustain its recent growth or lead to margin pressure. Sentiment is polarized between bulls highlighting Google's dominant AI stack as a long-term compounder and skeptics wary of the broader sector's reliance on circular capital investment cycles.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing significant selling pressure despite reporting strong quarterly earnings, as investors express skepticism over the company's aggressive, multi-billion dollar capital expenditure plans for AI infrastructure. The community remains deeply divided, with some investors viewing the stock as a prime dip-buying opportunity given its dominant market position, while others are concerned that rising costs and margin compression are unsustainable.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending as investors digest a massive Q1 earnings beat and AWS revenue acceleration, which was initially met with volatility before recovering in after-hours trading. The community is actively debating the impact of aggressive AI capital expenditure plans on near-term free cash flow versus the long-term potential of Amazon's custom silicon and cloud dominance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HIMS vs. TDOC: Which Digital Health Stock Offers Better Upside Now?

Hims & Hers and Teladoc Health are taking different paths in digital health, but which stock offers stronger upside now? Let's dive in.

<ul class="summary-bullets"><li>Semaglutide, the key ingredient in Novo Nordisk’s Wegovy and Ozempic, and Tirzepatide, sold by Eli Lilly as Zepbound and Mounjaro, would be excluded from bulk compounding.</li><li>The 503B Bulk List features drug ingredients considered medically necessary, allowing approved outsourcing facilities to use them to make compounded medicines.</li><li>The agency said there is insufficient evidence to justify broader access to compounded versions.</li></ul>The U.S. Food and Drug Administration, on Thursday, issued a proposal to exclude several popular weight-loss and diabetes drugs from its 503B bulks list, limiting how they can be compounded by outsourcing facilities.Semaglutide, the key ingredient in Novo Nordisk’s (NVO) Wegovy and Ozempic, and Tirzepatide, sold by Eli Lilly (LLY) as Zepbound and Mounjaro, would be excluded from bulk compounding. The Liraglutide.<h2 class="st-heading-2">FDA Sees No Clinical Need For Compounding Weight Loss Drugs</h2>The 503B Bulk List is an FDA-approved list of drug ingredients considered medically necessary, allowing approved outsourcing facilities to use them to make compounded medicines. In most cases, facilities can only compound drugs from bulk ingredients if they appear on this list or if the drug is officially in shortage.After reviewing available data, the FDA said it found no clear clinical need to allow compounding of these drugs from raw ingredients. The agency added that its decision is based on patient safety and medical necessity, noting that there is insufficient evidence to justify broader access to compounded versions.“When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need,” said FDA Commissioner Marty Makary.<h2 class="st-heading-2">FDA’s Concerns With Compounded Weight Loss Drugs</h2>The agency has been vocal about its issue with compounded weight-loss drugs. In February, the FDA said it intends to tighten rules around GLP-1 ingredients used in compounded medicines, citing concerns about quality, safety, and possible legal issues. Compounded drugs are not reviewed or approved by the FDA.The agency <a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-plunges-after-hours-fda-chief-warns-of-swift-action-on-copycat-drugs-after-novo-semaglutide-knockoff-launch/cZbnUBER4nQ">added</a> that compounded GLP-1 drugs should be used only when a patient’s needs cannot be met by an approved treatment. It also flagged risks such as improper storage, dosing mistakes, and counterfeit or misleadingly marketed products.Earlier this year, Novo Nordisk sued Hims &amp; Hers (HIMS) for patent infringement after HIMS launched a $49-per-month compounded version of Wegovy, claiming it used the same active ingredient as the branded drug. However, the two companies later reconciled,<a href="https://stocktwits.com/news-articles/markets/equity/hims-platform-novo-wegovy-availability-stock-focus/cZ3sTJFRIkI">&nbsp;teaming</a> up to offer FDA-approved versions of Wegovy and Ozempic at more affordable self-pay prices on the telehealth platform.Meanwhile, shares of LLY and NVO gained 9% and 5%, respectively, while HIMS edged 0.5% lower and Teladoc Health (TDOC) fell 2%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-lly-stock-up-earnings-mounjaro-zepbound/cZBMJq7Re4X">LLY Stock Up 7% Pre-Market As Mounjaro, Zepbound Sales Smash Expectations – Retail Bets On Run Toward $1,000</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the United States Food and Drug Administration (FDA) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

FDA Moves To Block Compounded Versions Of Popular Weight-Loss Drugs – NVO, LLY Stocks Gain

The FDA issued a proposal to exclude several popular weight-loss and diabetes drugs from being compounded by outsourcing facilities.

Equity

Teladoc Health (NYSE:TDOC) Shares Gap Down on Disappointing Earnings

Teladoc Health (NYSE:TDOC) Shares Gap Down After Earnings Miss...

Teladoc Health (NYSE:TDOC) Issues Earnings Results, Misses Estimates By $0.02 EPS

Teladoc Health (NYSE:TDOC - Get Free Report) issued its earnings results on Wednesday. The health services provider reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.34) by...

Here's What Key Metrics Tell Us About Teladoc (TDOC) Q1 Earnings

While the top- and bottom-line numbers for Teladoc (TDOC) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Teladoc (TDOC) Reports Q1 Loss, Beats Revenue Estimates

Teladoc (TDOC) delivered earnings and revenue surprises of -13.82% and +0.25%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Teladoc Health (NYSE:TDOC) Releases FY 2026 Earnings Guidance

Teladoc Health (NYSE:TDOC) updated its FY 2026 earnings guidance. The company provided EPS guidance of -1.050--0.750 for the period, compared to the consensus estimate of -0.930. The company also...

Teladoc Health (NYSE:TDOC) Releases Q2 2026 Earnings Guidance

Teladoc Health (NYSE:TDOC) updated its second quarter 2026 earnings guidance. The company provided EPS guidance of -0.300--0.200 for the period, compared to the consensus estimate of -0.220. The...

Hims & Hers Expands Digital-First Access to Personalized Healthcare

HIMS broadens digital-first care with Novo Nordisk GLP-1 access, new cancer detection and Labs tools, along with expansion into Canada and Europe.

Unlocking Q1 Potential of Teladoc (TDOC): Exploring Wall Street Estimates for Key Metrics

Evaluate the expected performance of Teladoc (TDOC) for the quarter ended March 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

$TDOC Q1 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.36 up 32.08% YoY
• Reported revenue of $613.85M down -2.47% YoY
• For the full year of 2026, Teladoc Health expects revenue of $2,481 - $2,576 million, Adjusted EBITDA of $267 - $306 million, and free cash flow of $130 - $170 million.

Stocktwits

Teladoc Health Inc

 Q1 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.36 up 32.08% YoY
• Reported revenue of $613.85M down -2.47% YoY
• For the full year of 2026, Teladoc Health expects revenue of $2,481 - $2,576 million, Adjusted EBITDA of $267 - $306 million, and free cash flow of $130 - $170 million.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

Apple Inc

Stocktwits Polls

Traders are closely tracking high short interest and institutional positioning, betting on an explosive price reversal to the upside.

Market sentiment is heavily centered on the potential for a takeover or strategic exit as a key catalyst for share price appreciation.

The transition of this service to insurance-based revenue is seen as a pivotal, make-or-break metric for future growth and profitability.

Investors are actively debating the leadership efficacy of CEO Chuck Divita, expressing sharp criticism regarding the company's turnaround progress.

Current Price	$6.12
Prev Close	$5.95
Open	$5.35
Dividend Yield	0.00%
50-Day Moving Average	$5.36
Beta	1.56
Avg. Volume	5.19M
PE Ratio	-5.22

52-Week High	$9.77
52-Week Low	$4.40
Market Capitalization	$1.07B
EPS (Annual)	-$1.14
Price to Book	0.77
Revenue Per Employee	$451,781.61

TDOC
Teladoc Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TDOC News

TDOCTeladoc Health Inc